Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.
BACKGROUND
The purpose of this study was to compare the effects of pemetrexed and carboplatin plus bevacizumab (PC + B) versus pemetrexed and carboplatin (PC) in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors (TKIs).


METHODS
Patients with EGFR-positive lung adenocarcinoma who had received second-line PC with or without bevacizumab harboring EGFR non-T790M mutations after progression on first-line EGFR-TKIs between April 2015 and 2017 at Tianjin Medical University Cancer Institute and Hospital were enrolled in the study. The primary endpoint was progression-free survival and secondary endpoints were overall survival, objective response rate, disease control rate, and safety.


RESULTS
A total of 85 patients were eligible for the study: 55 and 30 cases were enrolled in the PC and PC + B groups, respectively. The median progression-free survival was prolonged with PC + B compared to PC (median 8.2 vs. 5.1 months; P = 0.037). The objective response rate was improved with PC + B compared to PC (46.7% vs. 25.5%; P = 0.047) and overall survival prolonged with PC + B compared to PC (median 26.3 vs. 19.2 months; P = 0.012). Safety was similar to previous studies of bevacizumab in non-small cell lung cancer: one patient experienced grade 3 hypertension and proteinuria but did not require the discontinuation of therapy.


CONCLUSION
The addition of bevacizumab to PC was superior to PC alone as second-line therapy in patients with advanced non-T90M EGFR-positive lung adenocarcinoma. However, this result needs to be confirmed by prospective clinical trials.
['Jiang|Zhansheng|Z|', 'Zhang|Yu|Y|', 'Yang|Yinli|Y|', 'Yue|Zhensong|Z|', 'Pan|Zhanyu|Z|']
D000077192:Adenocarcinoma of Lung D000328:Adult D000368:Aged D000483:Alleles D019943:Amino Acid Substitution D000971:Antineoplastic Combined Chemotherapy Protocols D000068258:Bevacizumab D066246:ErbB Receptors D005260:Female D006801:Humans D053208:Kaplan-Meier Estimate D008297:Male D008875:Middle Aged D009154:Mutation D009367:Neoplasm Staging D000068437:Pemetrexed D047428:Protein Kinase Inhibitors D016896:Treatment Outcome
pemetrexed bevacizumab lung adenocarcinoma Epidermal growth factor receptor (EGFR) T790M